Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. (Q48508820)
Jump to navigation
Jump to search
scientific article published on 15 September 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. |
scientific article published on 15 September 2016 |
Statements
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy (English)
K A Ahmed
M I Echevarria
J A Arrington
D G Stallworth
C Hogue
A O Naghavi
S Kim
Y Kim
B G Patel
S Sarangkasiri
P A S Johnstone
S Sahebjam
N I Khushalani
P A Forsyth
L B Harrison
M Yu
A B Etame
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference